We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

We recently published a list of 11 Best Performing Healthcare Stocks to Buy Now. In this article, we are going to take a look ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter, with year-over-year revenue up 75.4 ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI delivered a record quarter, supported by strong revenue growth across its segments and a landmark $200 million agreement with AstraZeneca and Pathos. The company raised its full-year ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

Tempus AI Inc (NASDAQ:TEM) is an interesting AI story ... care for hard-to-treat illnesses and pharmaceutical companies like AstraZeneca (NASDAQ:AZN), with advances in medicine impossible without ...

Tempus AI, Inc. Class A (($TEM)) has held its Q1 earnings call. Read on for the main highlights of the call. Tempus AI, Inc. Class A recently held ...